公告提醒：愛必信所有產(chǎn)品和服務(wù)僅用于科學(xué)研究，不用于臨床應(yīng)用及其他用途提供產(chǎn)品和服務(wù)（也不為任何個人提供產(chǎn)品和服務(wù)）!

抑制劑描述：

產(chǎn)品名稱：ABT-199

產(chǎn)品別名：ABT199；GDC0199；ABT 199；GDC 0199；GDC-0199；Venetoclax

英文別名：ABT199;GDC0199;ABT 199;GDC 0199;GDC-0199;Venetoclax

靶點：Bcl-2 Family

CAS：1257044-40-8

純度：>98%

外觀：Powder

保存方法：store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -80℃ for six months.

描述：

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

溶解性：DMSO : 77.5 mg/mL (89.24 mM; Need ultrasonic)

體外研究：

ABT-199 shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Ki of 48 nM, > 444 nM and 245 nM, respectively. ABT-199 potently inhibits FL5.12-Bcl-2 cells, RS4;11 cells with EC50 of 4 nM and 8 nM, while shows low activity against FL5.12-Bcl-xL cells with EC50 of 261 nM. ABT-199 induces a rapid apoptosis in RS4;11 cells with cytochrome c release, caspase activation, the externalization of phosphatidylserine and the accumulation of sub-G0/G1 DNA. Quantitative immunoblotting reveals that sensitivity to ABT-199 correlated strongly with the expression of Bcl-2, including NHL, DLBCL, MCL, AML and ALL cell lines. ABT-199 also induces apoptosis in CLL with an average EC50 of 3.0 nM.

體內(nèi)研究：ABT-199 (100 mg/kg) causes a maximal tumor growth inhibition of 95% and tumor growth delay of 152% in RS4;11 xenografts. ABT-199 also inhibits xenograft growth (DoHH2, Granta-519) as a single agent or in combination with SDX-105 and other agents.

產(chǎn)品信息訂購：

產(chǎn)品更多信息請進入愛必信網(wǎng)站咨詢